Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Public ClinicalTrials.gov record NCT02320292. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-Agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation
Study identification
- NCT ID
- NCT02320292
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Mayo Clinic
- Other
- Enrollment
- 20 participants
Conditions and interventions
Conditions
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- Ann Arbor Stage I Grade 2 Follicular Lymphoma
- Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma
Interventions
- Quality-of-Life Assessment Other
- Rituximab Biological
- Yttrium Y-90 Ibritumomab Tiuxetan Radiation
Other · Biological · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 10, 2015
- Primary completion
- Feb 27, 2021
- Completion
- Nov 8, 2023
- Last update posted
- Jul 8, 2025
2015 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02320292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2025 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02320292 live on ClinicalTrials.gov.